Vaxcyte Prices Offerings Of Stock, Warrants, Convertible Notes To Raise Approx. $1 Bln

Vaxcyte priced public offerings of common stock, pre-funded warrants and convertible senior notes expected to generate approximately $1.0 billion in total proceeds. The financing provides substantial capital to the clinical-stage vaccine company, though the stock and warrant offerings may dilute existing shareholders.